PLSE Pulse Biosciences, Inc - Common Stock
$25,25
Fiyat · May 20, 2026
Temel veriler itibarıyla May 14, 2026
52 Haftlık Aralık
$13–$28
82% of range
Analist Derecelendirmesi
BUY
8 analysts
Fiyat Hedefi
$30
+19% upside
P/E (TTM)
—
ROE
—
Net Kâr Marjı
—
PLSE Hisse Senedi Özeti Fiyat, piyasa değeri, P/E, EPS, ROE, borç/öz sermaye, 52 haftalık aralık
Fiyat
$25.25
Piyasa Değeri
—
P/E (TTM)
—
EPS (TTM)
—
Gelir (TTM)
$350.0K
Temettü Verimi
—
ROE
—
D/E Borç/Özsermaye
—
52 Haftlık Aralık
$13 – $28
PLSE Hisse Senedi Fiyat Grafiği Teknik göstergeler ile günlük OHLCV — kaydır, yakınlaştır ve görünümünüzü özelleştirin
Configure
10 Yıllık Performans Gelir, net kar, marjlar ve EPS trendleri
Gelir ve Net Gelir
$350.0K
2020-12-31
→
2025-12-31
Hisse Başına Kâr
—
Serbest Nakit Akışı
—
2016-12-31
→
2023-12-31
Marjlar
—
Değerleme P/E, P/S, P/B, EV/EBITDA oranları — hisse senedi pahalı mı ucuz mu?
Metrik
5 Yıllık trend
PLSE
Akran Ortalaması
Kârlılık Brüt, faaliyet ve net kâr marjları; ROE, ROA, ROIC
Metrik
5 Yıllık trend
PLSE
Akran Ortalaması
Finansal Sağlık Borç, likidite, solventlik — bilanço gücü
Metrik
5 Yıllık trend
PLSE
Akran Ortalaması
Büyüme Gelir, EPS ve net gelir büyümesi: YOY, 3 Yıllık CAGR, 5 Yıllık CAGR
Metrik
5 Yıllık trend
PLSE
Akran Ortalaması
Revenue CAGR 3Y (Gelir 3 Yıllık Bileşik Büyüme Oranı)
-20.6%
—
Sermaye Verimliliği Aktif devir hızı, stok devir hızı, alacak devir hızı
Metrik
5 Yıllık trend
PLSE
Akran Ortalaması
PLSE Analist Uzlaşması Boğa ve ayı analist görüşleri, 12 aylık fiyat hedefi, yukarı yönlü potansiyel
AL
8 analist
- Güçlü Al 3 37,5%
- Al 4 50,0%
- Tut 1 12,5%
- Sat 0 0,0%
- Güçlü Sat 0 0,0%
12 Aylık Fiyat Hedefi
2 analist · 2026-05-16
Düşük
$30.00
Yüksek
$30.00
Medyan hedef
$30.00
+18,8%
Ortalama hedef
$30.00
+18,8%
Kazanç Geçmişi EPS gerçekleşen vs tahmin, sürpriz %, kazanma oranı, bir sonraki kazanç tarihi
Ort. Sürpriz
0.06%
| Dönem | EPS Gerçek | EPS Tahmin | Sürpriz |
|---|---|---|---|
| 31 Mart 2026 | $-0.24 | $-0.32 | 0.08% |
| 31 Aralık 2025 | $-0.26 | $-0.32 | 0.06% |
| 30 Eylül 2025 | $-0.29 | $-0.32 | 0.03% |
| 30 Haziran 2025 | $-0.20 | $-0.27 | 0.07% |
| 31 Mart 2025 | $-0.17 | — | — |
Eş Karşılaştırması Anahtar metrikler sektördeki benzerlerine karşı
| Hisse Sembolü | Piyasa Değeri | P/E | Gelir YoY | Net Kar Marjı | ROE | Brüt Kar Marjı |
|---|---|---|---|---|---|---|
| PLSE | — | — | — | — | — | — |
| TMDX | $4.17B | 25.0 | 37.1% | 31.4% | 48.1% | 59.9% |
| LMAT | $1.85B | 32.2 | 13.5% | 23.1% | 15.3% | 71.5% |
| AXGN | $1.54B | -96.3 | 20.2% | -7.0% | -13.0% | 74.3% |
| OMCL | $2.04B | 1132.5 | 6.5% | 0.17% | 0.16% | 42.5% |
| PRCT | $1.77B | -18.3 | 37.2% | -31.0% | -25.4% | 63.7% |
| ENOV | $1.52B | -1.3 | 6.7% | -52.7% | -58.5% | 59.8% |
| ATRC | $1.97B | -164.8 | 14.9% | -2.1% | -2.4% | 75.0% |
| ATEC | $3.16B | -21.9 | 24.9% | -18.8% | -792.1% | 69.6% |
| KMTS | $1.24B | -4.7 | 115.1% | -190.3% | 433.7% | 40.5% |
Tüm Temeller Tüm metrikler yıla göre — gelir tablosu, bilanço, nakit akışı
Gelir Tablosu 14
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Revenue | $350.0K | $0 | $0 | $700.0K | $1M | $0 | |
| Cost of Revenue | $539.0K | $0 | $0 | $12M | $2M | $0 | |
| R&D Expense | $45M | $32M | $28M | $21M | $29M | $26M | |
| SG&A Expense | $32M | $24M | $16M | $14M | $19M | $16M | |
| Operating Expenses | $77M | $56M | $44M | $59M | $64M | $50M | |
| Operating Income | $-77M | $-56M | $-44M | $-58M | $-63M | $-50M | |
| Interest Income | · | · | · | · | · | $114.0K | |
| Other Non-op | $-52.0K | $-18.0K | $1M | $-448.0K | $-646.0K | $114.0K | |
| Pretax Income | $73M | $54M | $-42M | $-59M | $-64M | $-50M | |
| Income Tax | $0 | $0 | $0 | $0 | $0 | $0 | |
| Net Income | $-73M | $-54M | $-42M | $-59M | $-64M | $-50M | |
| EPS (Basic) | $-1.08 | $-0.92 | $-0.85 | $-1.72 | $-2.28 | $-2.14 | |
| Shares (Basic) | 67,395,339 | 58,397,597 | 49,737,000 | 33,935,000 | 27,964,000 | 23,248,000 | |
| EBITDA | · | · | $-44M | $-58M | $-63M | $-50M |
Bilanço 26
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $81M | $118M | $44M | $61M | $44M | $12M | |
| Short-term Investments | · | · | · | · | · | $8M | |
| Receivables | $274.0K | $0 | · | $0 | $61.0K | · | |
| Inventory | $136.0K | $0 | · | $0 | $6M | · | |
| Prepaid Expense | $2M | $1M | $963.0K | $1M | $963.0K | $2M | |
| Current Assets | $83M | $119M | $45M | $62M | $45M | $22M | |
| PP&E (Net) | $1M | $1M | $2M | $2M | $2M | $2M | |
| PP&E (Gross) | $5M | $5M | $5M | $5M | $5M | $4M | |
| Accum. Depreciation | $4M | $4M | $3M | $3M | $2M | $2M | |
| Goodwill | $3M | $3M | $3M | $3M | $3M | $3M | |
| Intangibles | $575.0K | $1M | $2M | $3M | $2M | $4M | |
| Other Non-current Assets | $691.0K | $677.0K | $365.0K | $365.0K | $365.0K | $365.0K | |
| Total Assets | $95M | $132M | $59M | $78M | $59M | $41M | |
| Accounts Payable | $3M | $2M | $2M | $2M | $2M | $2M | |
| Accrued Liabilities | $4M | $7M | $4M | $3M | $4M | $5M | |
| Short-term Debt | · | · | $0 | $917.0K | $436.0K | · | |
| Current Liabilities | $8M | $10M | $7M | $6M | $7M | $8M | |
| Capital Leases | $6M | $8M | $8M | $9M | $8M | $11M | |
| Total Liabilities | $14M | $18M | $15M | $80M | $15M | $18M | |
| Total Debt | · | · | $0 | $0 | $436.0K | · | |
| Common Stock | $68.0K | $66.0K | $55.0K | $37.0K | $55.0K | $25.0K | |
| Retained Earnings | $-463M | $-390M | $-337M | $-295M | $-337M | $-173M | |
| AOCI | · | $0 | $0 | $0 | $0 | $-1.0K | |
| Stockholders' Equity | $81M | $115M | $44M | $-2M | $44M | $23M | |
| Liabilities + Equity | $95M | $132M | $59M | $78M | $59M | $41M | |
| Shares Outstanding | 67,839,689 | 65,925,503 | 55,144,000 | 37,235,000 | 55,144,000 | 25,550,000 |
Nakit Akışı 11
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Stock-based Comp | $21M | $14M | $7M | $5M | $15M | $10M | |
| Deferred Tax | · | · | $0 | $0 | $0 | $0 | |
| Amort. of Intangibles | $665.0K | $666.0K | $665.0K | $665.0K | $666.0K | $665.0K | |
| Operating Cash Flow | $-54M | $-36M | $-33M | $-47M | $-54M | $-35M | |
| CapEx | $315.0K | $125.0K | $121.0K | $401.0K | $437.0K | $441.0K | |
| Investing Cash Flow | $-335.0K | $-125.0K | $-121.0K | $-401.0K | $8M | $10M | |
| Stock Issued | · | · | $0 | $15M | $57M | $29M | |
| Net Stock Activity | · | · | $0 | $15M | $57M | · | |
| Financing Cash Flow | $17M | $110M | $16M | $80M | $63M | $31M | |
| Net Change in Cash | $-37M | $74M | $-17M | $33M | $16M | $6M | |
| Free Cash Flow | · | · | $-33M | $-47M | $-55M | $-36M |
Kârlılık 7
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Operating Margin | · | · | · | -8293.9% | -4443.9% | -43728.9% | |
| Net Margin | · | · | · | -8357.9% | -4489.4% | -43728.9% | |
| Pretax Margin | · | · | · | -8357.9% | -4489.4% | -43728.9% | |
| EBITDA Margin | · | · | · | -8293.9% | -4443.9% | -43728.9% | |
| ROA | · | · | -61.6% | -85.4% | -133.3% | -119.8% | |
| ROE | · | · | -87.5% | -2969.0% | -153.3% | -179.3% | |
| ROIC | · | · | -98.2% | 2582.6% | · | · |
Likidite ve Solventlik 3
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Current Ratio | · | · | 6.8 | 10.4 | 4.3 | 2.9 | |
| Quick Ratio | · | · | 6.6 | 10.2 | 3.4 | 2.7 | |
| Debt / Equity | · | · | 0.0 | 0.0 | 0.0 | · |
Verimlilik 3
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Asset Turnover | · | · | 0.0 | 0.0 | 0.0 | 0.0 | |
| Inventory Turnover | · | · | · | 4.1 | 0.2 | · | |
| Receivables Turnover | · | · | · | 23.0 | 46.5 | · |
Büyüme Oranları 2
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Revenue YoY | · | · | · | -50.6% | · | · | |
| Revenue CAGR 3Y | -20.6% | · | · | · | · | · |
Değerleme (TTM) 12
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Revenue TTM | $350.0K | $0 | $0 | $700.0K | $1M | $0 | |
| Net Income TTM | $-73M | $-54M | $-42M | $-59M | $-64M | $-50M | |
| Market Cap | · | · | $675M | $103M | $440M | $610M | |
| Enterprise Value | · | · | $631M | $42M | $412M | · | |
| P/S | · | · | · | 147.3 | 310.4 | · | |
| P/B | · | · | 15.2 | -45.9 | 12.3 | 26.6 | |
| P / Tangible Book | 12.1 | 10.4 | 17.0 | · | 11.1 | 37.6 | |
| P / Cash Flow | · | · | -20.4 | -2.2 | -8.1 | -17.2 | |
| P / FCF | · | · | -20.4 | -2.2 | -8.1 | -17.0 | |
| EV / EBITDA | · | · | -14.5 | -0.7 | -6.5 | · | |
| EV / FCF | · | · | -19.0 | -0.9 | -7.6 | · | |
| EV / Revenue | · | · | · | 60.0 | 290.5 | · |
Gelir Tablosu 15
| Metrik | Eğilim | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $401.0K | $264.0K | $86.0K | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $-9.0K | $0 | $265.0K | |
| Cost of Revenue | $370.0K | $260.0K | $279.0K | · | $0 | $0 | $0 | · | · | · | $0 | $0 | $0 | $1M | $8M | $1M | |
| R&D Expense | $13M | $11M | $11M | $12M | $10M | $11M | $8M | $7M | $7M | $8M | $7M | $7M | $6M | $4M | $5M | $5M | |
| SG&A Expense | $7M | $7M | $9M | $8M | $8M | $10M | $6M | $4M | $4M | $5M | $4M | $4M | $4M | $3M | $3M | $4M | |
| Operating Expenses | $20M | $19M | $20M | $20M | $18M | $20M | $14M | $12M | $11M | $13M | $11M | $10M | $10M | $9M | $18M | $14M | |
| Operating Income | $-19M | $-18M | $-20M | $-20M | $-18M | $-20M | $-14M | $-12M | $-11M | $-13M | $-11M | $-10M | $-10M | $-9M | $-18M | $-14M | |
| Other Non-op | $-24.0K | $-2M | $-19.0K | $1M | $-6.0K | $-838.0K | $-1.0K | $343.0K | $478.0K | $600.0K | $686.0K | $317.0K | $-239.0K | $-452.0K | $-14.0K | $18.0K | |
| Pretax Income | · | · | · | $-19M | $-17M | $88M | $-13M | $-11M | $-10M | $-12M | $-11M | $-10M | $-10M | $-9M | $-18M | $-14M | |
| Income Tax | · | · | · | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | |
| Net Income | $-19M | $-17M | $-19M | $-19M | $-17M | $-19M | $-13M | $-11M | $-10M | $-12M | $-11M | $-10M | $-10M | $-9M | $-18M | $-14M | |
| EPS (Basic) | $-0.27 | $-0.26 | $-0.29 | $-0.28 | $-0.25 | $-0.33 | $-0.21 | $-0.20 | $-0.18 | $-0.18 | $-0.19 | $-0.22 | $-0.26 | $-0.21 | $-0.49 | $-0.44 | |
| EPS (Diluted) | · | · | · | · | · | · | · | · | · | · | · | · | · | · | $-0.49 | $-0.44 | |
| Shares (Basic) | 67,994,566 | -134,391,661 | 67,385,000 | 67,276,000 | 67,125,967 | -116,972,403 | 61,066,000 | 57,180,000 | 57,124,000 | -90,605,000 | 56,866,000 | 46,086,000 | 37,390,000 | -64,460,000 | 37,158,000 | 31,492,000 | |
| Shares (Diluted) | · | · | · | · | · | · | · | · | · | · | · | · | · | · | 37,158,000 | 31,492,000 | |
| EBITDA | $-19M | · | $-20M | $-20M | $-18M | · | $-14M | $-12M | $-11M | · | $-11M | $-10M | $-10M | · | $-18M | $-14M |
Bilanço 25
| Metrik | Eğilim | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $68M | $81M | $95M | $106M | $119M | $118M | $79M | $26M | $35M | $44M | $50M | $59M | $54M | $61M | $69M | $15M | |
| Receivables | $157.0K | $274.0K | $15.0K | · | · | $0 | · | · | · | · | · | · | · | · | $5.0K | $8.0K | |
| Inventory | $206.0K | $136.0K | $57.0K | $51.0K | $30.0K | $0 | · | · | · | · | · | · | · | · | $750.0K | $8M | |
| Prepaid Expense | $2M | $2M | $2M | $2M | $2M | $1M | $1M | $1M | $964.0K | $963.0K | $1M | $1M | $849.0K | $1M | $1M | $1M | |
| Current Assets | $71M | $83M | $97M | $108M | $121M | $119M | $80M | $27M | $36M | $45M | $52M | $60M | $55M | $62M | $71M | $24M | |
| PP&E (Net) | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | |
| PP&E (Gross) | · | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $5M | |
| Accum. Depreciation | · | $4M | $4M | $4M | $4M | $4M | $4M | $4M | $4M | $3M | $3M | $3M | $3M | $3M | $3M | $3M | |
| Goodwill | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $3M | |
| Intangibles | $408.0K | $575.0K | $741.0K | $907.0K | $1M | $1M | $1M | $2M | $2M | $2M | $2M | $2M | $2M | $3M | $3M | $3M | |
| Other Non-current Assets | $575.0K | $691.0K | $705.0K | $677.0K | $678.0K | $677.0K | $646.0K | $714.0K | $365.0K | $365.0K | $365.0K | $365.0K | $365.0K | $365.0K | $365.0K | $365.0K | |
| Total Assets | $82M | $95M | $109M | $120M | $133M | $132M | $93M | $40M | $49M | $59M | $66M | $75M | $70M | $78M | $88M | $41M | |
| Accounts Payable | $3M | $3M | $3M | $3M | $2M | $2M | $2M | $2M | $2M | $2M | $1M | $2M | $2M | $2M | $2M | $2M | |
| Accrued Liabilities | $5M | $4M | $5M | $5M | $4M | $7M | $4M | $3M | $2M | $4M | $3M | $3M | $3M | $3M | $4M | $5M | |
| Short-term Debt | · | · | · | · | · | · | · | · | · | · | $0 | $0 | $801.0K | $917.0K | · | · | |
| Current Liabilities | $10M | $8M | $10M | $9M | $8M | $10M | $7M | $6M | $5M | $7M | $5M | $6M | $7M | $6M | $7M | $8M | |
| Capital Leases | $6M | $6M | $6M | $7M | $7M | $8M | $7M | $7M | $8M | $8M | $8M | $9M | $9M | $9M | $9M | $10M | |
| Total Liabilities | $15M | $14M | $16M | $16M | $15M | $18M | $14M | $13M | $13M | $15M | $14M | $14M | $81M | $80M | $81M | $17M | |
| Total Debt | · | · | · | · | · | · | · | · | · | · | $0 | $0 | $801.0K | · | · | · | |
| Common Stock | $68.0K | $68.0K | $68.0K | $67.0K | $67.0K | $66.0K | $62.0K | $55.0K | $55.0K | $55.0K | $55.0K | $55.0K | $37.0K | $37.0K | $37.0K | $37.0K | |
| Retained Earnings | $-482M | $-463M | $-446M | $-426M | $-407M | $-390M | $-371M | $-358M | $-347M | $-337M | $-325M | $-314M | $-305M | $-295M | $-286M | $-267M | |
| AOCI | · | · | · | · | $0 | · | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | · | · | |
| Stockholders' Equity | $66M | $81M | $93M | $104M | $118M | $115M | $79M | $27M | $36M | $44M | $52M | $60M | $-11M | $-2M | $6M | $23M | |
| Liabilities + Equity | $82M | $95M | $109M | $120M | $133M | $132M | $93M | $40M | $49M | $59M | $66M | $75M | $70M | $78M | $88M | $41M | |
| Shares Outstanding | 68,225,067 | 67,839,689 | 67,738,000 | 67,278,000 | 67,274,000 | 65,925,503 | 61,516,000 | 55,228,000 | 55,225,000 | 55,144,000 | 54,991,000 | 54,771,000 | 37,593,000 | 37,235,000 | 37,228,000 | 37,126,000 |
Nakit Akışı 9
| Metrik | Eğilim | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $2M | $5M | $6M | $5M | $6M | $7M | $3M | $2M | $2M | $3M | $2M | $1M | $896.0K | $748.0K | $723.0K | $2M | |
| Amort. of Intangibles | $167.0K | $166.0K | $166.0K | $167.0K | $166.0K | $166.0K | $167.0K | $166.0K | $167.0K | $166.0K | $166.0K | $166.0K | $167.0K | $166.0K | $166.0K | $167.0K | |
| Operating Cash Flow | $-15M | $-15M | $-13M | $-13M | $-14M | $-9M | $-9M | $-8M | $-10M | $-7M | $-10M | $-9M | $-7M | $-8M | $-11M | $-13M | |
| CapEx | $33.0K | $105.0K | $62.0K | $103.0K | $45.0K | $53.0K | $38.0K | $29.0K | $5.0K | $43.0K | $23.0K | $16.0K | $39.0K | $41.0K | $62.0K | $19.0K | |
| Investing Cash Flow | $-33.0K | $-105.0K | $-62.0K | $-123.0K | $-45.0K | $-53.0K | $-38.0K | $-29.0K | $-5.0K | $-43.0K | $-23.0K | $-16.0K | $-39.0K | $-41.0K | $-62.0K | $-19.0K | |
| Stock Issued | · | · | · | · | · | · | · | · | · | · | $0 | · | · | $-29.0K | $-70.0K | · | |
| Financing Cash Flow | $2M | $381.0K | $2M | $0 | $15M | $48M | $62M | $-265.0K | $305.0K | $804.0K | $2M | $14M | $-432.0K | $-17.0K | $65M | $15M | |
| Net Change in Cash | $-12M | $-14M | $-11M | $-13M | $1M | $39M | $53M | $-9M | $-9M | $-6M | $-8M | $5M | $-7M | $-8M | $54M | $2M | |
| Free Cash Flow | $-15M | · | · | · | $-14M | · | · | · | $-10M | · | · | · | $-7M | · | · | · |
Kârlılık 6
| Metrik | Eğilim | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -4775.6% | · | -23682.6% | · | · | · | · | · | · | · | · | · | · | · | · | -5288.3% | |
| Net Margin | -4633.7% | · | -22540.7% | · | · | · | · | · | · | · | · | · | · | · | · | -5281.5% | |
| EBITDA Margin | -4775.6% | · | -23682.6% | · | · | · | · | · | · | · | · | · | · | · | · | -5288.3% | |
| ROA | -17.3% | · | -19.2% | -23.9% | -18.4% | · | -16.0% | -19.8% | -17.0% | · | -13.8% | -17.2% | -17.9% | · | -23.3% | -23.2% | |
| ROE | -20.1% | · | -22.6% | -29.2% | -21.7% | · | -19.3% | -26.0% | -79.1% | · | -36.2% | -23.6% | -193.5% | · | -67.3% | -33.7% | |
| ROIC | · | · | · | -19.4% | -15.2% | · | -17.3% | -43.5% | -29.2% | · | -21.6% | -16.9% | 96.9% | · | · | · |
Likidite ve Solventlik 3
| Metrik | Eğilim | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 7.3 | · | 10.0 | 12.0 | 15.6 | · | 11.9 | 4.6 | 7.1 | · | 9.5 | 10.7 | 7.9 | · | 10.2 | 3.1 | |
| Quick Ratio | 7.0 | · | 9.8 | 11.8 | 15.4 | · | 11.7 | 4.4 | 6.9 | · | 9.3 | 10.5 | 7.7 | · | 9.9 | 2.0 | |
| Debt / Equity | · | · | · | · | · | · | · | · | · | · | 0.0 | 0.0 | -0.1 | · | · | · |
Verimlilik 3
| Metrik | Eğilim | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | |
| Inventory Turnover | 3.1 | · | 0.7 | · | · | · | · | · | · | · | · | · | · | · | 3.3 | 0.3 | |
| Receivables Turnover | 4.5 | · | 8.6 | · | · | · | · | · | · | · | · | · | · | · | 0.0 | 66.2 |
Değerleme (TTM) 12
| Metrik | Eğilim | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $487.0K | · | $86.0K | $0 | $0 | · | $0 | $0 | $0 | · | $0 | $265.0K | $709.0K | · | $1M | · | |
| Net Income TTM | $-74M | · | $-68M | $-60M | $-51M | · | $-45M | $-42M | $-40M | · | $-48M | $-52M | $-59M | · | $-64M | $-61M | |
| Market Cap | $1.47B | · | $1.20B | $1.02B | $1.08B | · | $1.08B | $618M | $481M | · | $222M | $394M | $126M | · | $86M | $57M | |
| Enterprise Value | · | · | · | · | · | · | · | · | · | · | $171M | $335M | $73M | · | · | · | |
| P/S | 3024.6 | · | 13941.4 | · | · | · | · | · | · | · | · | 1486.1 | 178.2 | · | 66.7 | · | |
| P/B | 22.2 | · | 12.9 | 9.7 | 9.1 | · | 13.6 | 22.9 | 13.3 | · | 4.2 | 6.5 | -11.8 | · | 13.8 | 2.4 | |
| P / Tangible Book | 23.3 | · | 13.4 | 10.1 | 9.4 | · | 14.4 | 27.3 | 15.1 | · | 4.7 | 7.1 | · | · | 125.7 | 3.2 | |
| P / Cash Flow | -100.9 | · | · | · | -80.1 | · | · | · | -49.2 | · | · | · | -19.2 | · | · | · | |
| P / FCF | -100.7 | · | · | · | -79.8 | · | · | · | -49.2 | · | · | · | -19.1 | · | · | · | |
| EV / EBITDA | · | · | · | · | · | · | · | · | · | · | -15.2 | -32.8 | -7.6 | · | · | · | |
| EV / FCF | · | · | · | · | · | · | · | · | · | · | · | · | -11.0 | · | · | · | |
| EV / Revenue | · | · | · | · | · | · | · | · | · | · | · | 1264.4 | 103.0 | · | · | · |
Finansal Tablolar Gelir tablosu, bilanço, nakit akışı — yıllık, son 5 yıl
Gelir Tablosu
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Gelir | $350.0K | $0 | $0 | $700.0K | $1M |
| Faaliyet Kâr Marjı % | — | — | — | -8293.9% | -4443.9% |
| Net Gelir | $-73M | $-54M | $-42M | $-59M | $-64M |
Bilanço
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Borç / Öz Sermaye | — | — | 0.0 | 0.0 | 0.0 |
| Cari Oran | — | — | 6.8 | 10.4 | 4.3 |
| Cari Oran | — | — | 6.6 | 10.2 | 3.4 |
Nakit Akışı
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Serbest Nakit Akışı | — | — | $-33M | $-47M | $-55M |
Son Haberler Bu şirketten bahseden son manşetler
- Pulse Biosciences CEO Satın Aldı 15.000 Şirket Hissesini. Yatırımcılar İçin Bu Ne Anlama Geliyor.
- Pulse Biosciences (PLSE) Pivotal Atrial Fibrillation Trial'ında İlk Hastalarını Kaydettirdi
- Pulse Biosciences Liane Teplitsky'yi CCO Olarak Atadı, David Kenigsberg'in Rolünü Tam Zamanlı CMO Olarak Genişletti
Metriklerim Kişisel izleme listeniz — Tam Temeller'den seçilen satırlar
📊
Sizin için önemli olan metrikleri seçin — yukarıdaki Tam Temeller'deki herhangi bir satırın yanındaki ➕ düğmesine tıklayın.
Seçiminiz kaydedildi ve tüm hisse senetlerinde sizinle birlikte gelir.